Announced Thu, 25 Jun · 18:20 IST
Jagsonpal Pharmaceuticals appoints Anil Kumar Matai as Independent Director
Management Changes View source PDF
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+7.6%1-day move
₹223.00
prior close
₹222.32
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.5+2.4+2.7—+7.6+6.5+5.3+6.6+6.7+2.6+0.0———
Up moveDown movePending
AI summary
Jagsonpal Pharmaceuticals has appointed Mr. Anil Kumar Matai as an Additional Non-Executive Independent Director effective June 25, 2026, for a 5-year term, subject to shareholder approval. He has over 35 years of experience across pharma, healthcare, and consumer sectors, and is currently Director General of OPPI. His prior roles include CEO of Novartis India and MD of Zydus Healthcare. He is not debarred by any authority.
Likely market impact
Brings seasoned pharma leadership to the board; appointment pending shareholder approval at the next general meeting.